Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR7 | P34969 | 2/20 | 0.45 |
| ▸ | PPARG | P37231 | 1/20 | 0.40 |
| ▸ | ELANE | P08246 | 3/20 | 0.39 |
| ▸ | USP1 | O94782 | 2/20 | 0.39 |
| ▸ | METAP2 | P50579 | 2/20 | 0.39 |
| ▸ | HTR3E | A5X5Y0 | 2/20 | 0.38 |
| ▸ | HTR3B | O95264 | 2/20 | 0.38 |
| ▸ | HTR3A | P46098 | 2/20 | 0.38 |
| ▸ | HTR3D | Q70Z44 | 2/20 | 0.38 |
| ▸ | HTR3C | Q8WXA8 | 2/20 | 0.38 |
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | HTR1A | P08908 | 1/20 | 0.36 |
| ▸ | HTR2C | P28335 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6692106 | 0.89 | HTR3E (0.41) | ELANEUSP1METAP2HTR3EHTR3B | |
| SCHEMBL6700742 | 0.89 | PTGDR2 (0.43) | HTR7ELANEUSP1METAP2HTR3E | |
| SCHEMBL6700106 | 0.87 | KMT2A (0.46) | ELANEUSP1HTR3EHTR3BHTR3A | |
| SCHEMBL6693288 | 0.84 | HTR7 (0.48) | HTR7PPARGHTR1AHTR2C | |
| SCHEMBL6226643 | 0.82 | HTR3E (0.42) | ELANEUSP1METAP2HTR3EHTR3B | |
| SCHEMBL6224819 | 0.77 | CYP1A2 (0.43) | ELANEUSP1METAP2HTR3EHTR3B | |
| SCHEMBL6225287 | 0.76 | BRD4 (0.45) | METAP2HRH4HTT | |
| SCHEMBL6696187 | 0.75 | USP1 (0.44) | PPARGELANEUSP1METAP2HTR3E | |
| SCHEMBL6223653 | 0.75 | CYP11B1 (0.54) | ELANEHTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL6249947 | 0.74 | BRD4 (0.44) | METAP2HRH4HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040229874-A1 | 5HT7 Antagonists and inverse agonists | PFIZER INC. | 2004-11-18 | — | — | US | claimed |
| US-20040229874-A1 | 5HT7 Antagonists and inverse agonists | PFIZER INC. | 2004-11-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040229874-A1 | 5HT7 Antagonists and inverse agonists | HTR7, HTR1A, HTR1B | HTR7 1/4885PPARG 1245/4885ELANE 4713/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.